Last updated: September 30, 2026
MAXALT, Merck’s brand for rizatriptan benzoate, generated its commercial value as an early oral triptan for acute migraine treatment. Its U.S. market has since shifted to low-priced generic rizatriptan after loss of branded exclusivity. Maxalt’s financial trajectory followed a standard small-molecule lifecycle: rapid uptake after launch, mature-brand competition from other triptans, patent expiry, generic substitution, and a steep decline in branded revenue.
What is MAXALT and how is it used?
MAXALT is the brand name for rizatriptan benzoate, a selective serotonin 5-HT1B/1D receptor agonist. FDA approved MAXALT tablets in 1998 and MAXALT-MLT orally disintegrating tablets in 2001 for the acute treatment of migraine attacks with or without aura in adults. The product is not indicated for migraine prevention or cluster-headache treatment (FDA, 2024a).
MAXALT product profile
| Attribute |
MAXALT details |
| Active ingredient |
Rizatriptan benzoate |
| Drug class |
Triptan; 5-HT1B/1D receptor agonist |
| Initial U.S. approval |
1998 |
| Original sponsor |
Merck & Co. |
| Dosage forms |
Immediate-release tablet; orally disintegrating tablet |
| Common strengths |
5 mg and 10 mg |
| Primary use |
Acute treatment of migraine |
| FDA route |
New Drug Application |
| Current commercial position |
Mature brand with generic competition |
| Main substitutes |
Sumatriptan, naratriptan, zolmitriptan, eletriptan, frovatriptan, ubrogepant and rimegepant |
The 10-mg dose is generally the higher-strength commercial presentation, while the 5-mg dose is used where a lower dose is appropriate. MAXALT-MLT was designed to dissolve orally without water, giving the product a convenience advantage over conventional tablets, but that advantage did not prevent generic erosion once the underlying market exclusivity expired.
When did MAXALT lose exclusivity?
MAXALT lost meaningful U.S. market exclusivity when generic rizatriptan products entered the market after expiration of the principal composition-of-matter patent and related regulatory protections. The core U.S. patent estate was not capable of sustaining branded pricing after the early 2010s.
MAXALT exclusivity timeline
| Event |
Approximate date |
Commercial effect |
| FDA approval of MAXALT tablets |
1998 |
Began U.S. commercial exclusivity |
| FDA approval of MAXALT-MLT |
2001 |
Expanded delivery-format protection |
| Core patent expiry period |
Early to mid-2010s |
Opened pathway for generic entry |
| Generic rizatriptan approvals and launches |
2013 onward |
Reduced branded pricing power |
| Mature generic market |
Late 2010s onward |
Shifted volume and value to generic suppliers |
Public FDA records identify MAXALT and MAXALT-MLT as products with discontinued branded presentations, while generic rizatriptan remains available through multiple abbreviated new drug applications (FDA, 2024b). The exact commercial date at which a particular generic achieved first launch depended on the applicant, dosage form, and patent-certification status.
What patents protected MAXALT?
The principal patent estate covered rizatriptan and related pharmaceutical compositions. U.S. Patent No. 5,298,532, assigned to Merck, was one of the key patents associated with rizatriptan protection. Its term ran into the early 2010s, subject to applicable patent-term adjustments, regulatory extensions, and pediatric exclusivity.
The estate also included protection relating to pharmaceutical formulations and orally disintegrating dosage forms. Those patents had less strategic value after generic manufacturers developed approved immediate-release and orally disintegrating products through the ANDA pathway.
Patent coverage varied by jurisdiction. U.S. protection was the main driver of the product’s original commercial value, while European and other national rights expired on different dates based on filing history, patent-term rules, supplementary protection certificates, and local litigation.
What is the Orange Book status of MAXALT?
MAXALT’s Orange Book position is principally historical. FDA’s Orange Book identifies approved MAXALT products and associated patent and exclusivity records, but the brand has no current ability to block generic competition through an active, commercially material exclusivity period (FDA, 2024b).
The relevant regulatory distinction is between:
- The original MAXALT and MAXALT-MLT NDAs.
- Patent listings associated with those NDAs.
- Later ANDAs for generic rizatriptan tablets and orally disintegrating tablets.
- Product marketing status, which can differ from formal approval status.
A discontinued brand product can remain listed in FDA databases even when the sponsor is no longer actively marketing it. That database status should not be treated as evidence of current branded sales.
Which companies challenged MAXALT patents?
Generic manufacturers challenged or designed around the MAXALT patent estate through ANDA filings and patent certifications. Public FDA records show generic rizatriptan products from multiple manufacturers, including major generic suppliers and contract-manufacturing companies.
Because generic applicants can enter after patent expiry without a public trial establishing infringement, the commercial record does not require a completed Paragraph IV trial for every supplier. The key mechanism was the ANDA pathway, including Paragraph III certifications where the applicant accepted delayed entry until patent expiry and Paragraph IV certifications where the applicant alleged that listed patents were invalid, unenforceable or would not be infringed.
How did Paragraph IV challenges affect MAXALT?
Paragraph IV filings can create a 30-month stay of FDA approval for an ANDA when the brand sponsor files an infringement action within the statutory period. They can also create 180-day exclusivity for the first qualifying generic applicant. The commercial effect depends on:
- Whether the listed patent is still enforceable.
- Whether the sponsor files suit.
- Whether the parties settle.
- Whether the first applicant launches at risk.
- Whether other generic applicants receive tentative or final approval.
For MAXALT, the principal economic effect came from loss of effective patent exclusivity rather than from a durable litigation barrier. Once multiple generic versions became available, price competition reduced the value of any residual formulation differentiation.
How strong is the MAXALT patent estate?
The MAXALT patent estate was commercially strong during the initial lifecycle but weak as a current barrier to generic entry.
Patent-strength assessment
| Factor |
Assessment |
| Active ingredient protection |
Historically strong, now expired or commercially exhausted |
| Tablet formulation protection |
Limited current blocking power |
| Orally disintegrating formulation |
Provided differentiation but did not preserve brand pricing |
| Method-of-use protection |
Narrow relative to broad migraine treatment demand |
| Manufacturing protection |
Low-to-moderate barrier for capable generic manufacturers |
| Biosimilar protection |
Not applicable; rizatriptan is a small molecule |
| Current litigation leverage |
Low |
| Current ability to support premium pricing |
Minimal |
The absence of biosimilar risk is important. MAXALT is a chemically synthesized small molecule, not a biologic. Generic companies use ANDAs rather than the biosimilar pathway. The relevant competitive threats are generic substitution, therapeutic substitution among triptans, and migration to newer non-triptan migraine drugs.
What generic entry risks exist for MAXALT?
Generic entry risk is effectively realized rather than prospective. Generic rizatriptan is established in the U.S. market, and pharmacy substitution has materially reduced the branded product’s addressable revenue.
Generic launch scenarios
| Scenario |
Likely outcome |
| Single generic entrant |
Moderate price decline; some residual brand retention |
| Several tablet suppliers |
Rapid price compression and high substitution |
| Generic orally disintegrating products |
Erodes MAXALT-MLT’s convenience advantage |
| Low-cost pharmacy channels |
Further reduces branded demand |
| Supply disruption among generics |
Temporary price or share volatility, not durable brand recovery |
| Brand withdrawal |
Generic products become the primary supply source |
The main commercial risk is not a future launch event. It is continued erosion of any remaining branded prescriptions and reimbursement preference. Generic manufacturers can compete on price because the active ingredient, dosage strengths, and clinical use are well established.
What was MAXALT’s financial trajectory?
Merck did not consistently report MAXALT as a separately disclosed revenue line in its public financial statements. The company generally grouped products into broader therapeutic or franchise categories. As a result, a precise annual MAXALT revenue series cannot be established from Merck’s consolidated filings alone.
Financial lifecycle
| Period |
Financial position |
| Late 1990s |
Launch-stage investment and prescription expansion |
| Early to mid-2000s |
Peak commercial contribution as a leading triptan brand |
| Late 2000s |
Mature-brand phase with competition from other triptans |
| Early 2010s |
Patent expiry and generic-entry preparation |
| Mid-2010s |
Sharp reduction in branded price and volume |
| Late 2010s onward |
Residual or discontinued-brand economics; value shifted to generics |
MAXALT’s financial trajectory was affected by four factors.
1. Triptan market competition
MAXALT competed with sumatriptan, the largest and usually lowest-cost triptan, along with naratriptan, zolmitriptan, eletriptan and frovatriptan. Prescribers selected among these products based on onset, tolerability, recurrence, dosing convenience, formulary placement and patient response.
MAXALT’s rapid-onset positioning supported adoption, but triptans had limited ability to sustain premium pricing once multiple alternatives became generic.
2. Generic substitution
After patent expiry, payers and pharmacies had a strong incentive to substitute generic rizatriptan. The result was a transfer of economic value from Merck to generic manufacturers and wholesalers. Brand revenue declined faster than clinical use because migraine patients continued to require acute treatment even as the product’s price fell.
3. Newer migraine therapies
The launch of CGRP-targeting drugs introduced a second competitive pressure. Oral gepants such as ubrogepant and rimegepant offered acute migraine treatment without the vasoconstrictive mechanism associated with triptans. These products were priced materially above generic rizatriptan but could capture patients with inadequate triptan response, intolerance or cardiovascular restrictions.
The newer products did not eliminate triptan demand. Generic triptans retained an important role because of low cost, broad physician familiarity and established efficacy.
4. Delivery-format differentiation
MAXALT-MLT’s orally disintegrating format offered a practical benefit for patients who had difficulty swallowing during migraine attacks. That benefit supported product differentiation before generic orally disintegrating rizatriptan became available. Formulation differentiation alone was insufficient to preserve a premium after competing products achieved FDA approval.
How does MAXALT compare with competing migraine drugs?
| Product |
Active ingredient |
Drug type |
Current competitive position |
| MAXALT |
Rizatriptan |
Triptan |
Legacy brand; generic substitution |
| Imitrex |
Sumatriptan |
Triptan |
Large generic base; broad dosage forms |
| Relpax |
Eletriptan |
Triptan |
Generic competition |
| Amerge |
Naratriptan |
Triptan |
Generic competition; longer duration |
| Zomig |
Zolmitriptan |
Triptan |
Generic competition; multiple forms |
| Frova |
Frovatriptan |
Triptan |
Generic competition; longer half-life |
| Ubrelvy |
Ubrogepant |
CGRP antagonist |
Branded acute-treatment competitor |
| Nurtec ODT |
Rimegepant |
CGRP antagonist |
Branded acute and preventive option |
| Zavzpret |
Zavegepant |
CGRP antagonist nasal spray |
Branded non-oral acute option |
MAXALT’s main advantage is cost-effective, familiar triptan therapy. Its principal disadvantages are generic commoditization and the class limitations of triptans, including contraindications or precautions involving certain cardiovascular and cerebrovascular conditions.
What is the FDA regulatory status of MAXALT?
FDA approved MAXALT for acute migraine treatment, not prevention. The product label includes contraindications involving patients with ischemic coronary artery disease, coronary vasospasm, peripheral vascular disease, ischemic bowel disease, uncontrolled hypertension and certain cerebrovascular conditions. It also warns against use with other 5-HT1 agonists or ergot-type medications within specified intervals (FDA, 2024a).
Generic rizatriptan products must demonstrate pharmaceutical equivalence and bioequivalence to the applicable reference product. They do not need to repeat the full clinical development program conducted for MAXALT.
Are there licensing deals associated with MAXALT?
Merck was the principal commercial sponsor of MAXALT. The product’s development history involved licensing and collaboration arrangements associated with rizatriptan research, but the major commercial event was Merck’s launch and marketing of the product rather than a later licensing transaction that preserved exclusivity.
No publicly material current licensing arrangement gives MAXALT a meaningful growth platform. The commercial rights are tied to a mature, largely genericized product.
What patent litigation affects MAXALT?
MAXALT does not have a current litigation profile comparable to active blockbuster products with pending composition-of-matter patents, patent-term extensions or ongoing Paragraph IV settlements. Historical patent disputes may have involved ANDA filings and formulation claims, but current commercial exposure is governed primarily by generic availability and reimbursement.
Settlement agreements and entry dates
Generic settlements can establish delayed launch dates, authorized-generic arrangements, or restrictions on certain dosage forms. The existence of a settlement does not by itself indicate continuing brand strength. For MAXALT, the practical result of entry agreements was eventually overtaken by the expiration of core rights and the arrival of multiple generic suppliers.
What manufacturing and intellectual-property barriers remain?
Manufacturing barriers are modest. Rizatriptan is a synthetic small molecule with established analytical methods and conventional oral dosage forms. The main technical challenges involve:
- Consistent active-pharmaceutical-ingredient purity.
- Control of polymorphic or solid-state properties.
- Tablet disintegration and dissolution.
- Taste and mouthfeel for orally disintegrating tablets.
- Packaging that limits moisture exposure.
- Reliable supply of active ingredient and finished dosage forms.
These issues can delay an individual applicant, but they do not create a durable market-wide barrier. A generic manufacturer does not need to replicate every aspect of Merck’s historical manufacturing process if it meets FDA quality, bioequivalence and stability requirements.
What is MAXALT’s current revenue exposure?
Current branded revenue exposure is low relative to Merck’s major products and is not separately quantified in Merck’s public reporting. The economic value of rizatriptan remains in the therapeutic market, but most of that value is captured by generic manufacturers, pharmacies and payers rather than by the original brand owner.
For investors and licensing teams, MAXALT should be treated as:
- A mature genericized small molecule.
- A low-value brand asset unless supported by an active commercialization strategy.
- A product with limited patent-driven upside.
- A possible portfolio asset only where manufacturing cost, niche distribution or formulation rights create a specific advantage.
Key Takeaways
- MAXALT is Merck’s rizatriptan brand for acute migraine treatment.
- FDA approved MAXALT tablets in 1998 and MAXALT-MLT in 2001.
- Core exclusivity expired in the early to mid-2010s, enabling generic rizatriptan entry.
- Generic competition has largely eliminated branded pricing power.
- MAXALT is a small molecule, so biosimilar risk is irrelevant; generic ANDA competition is the relevant pathway.
- The orally disintegrating MAXALT-MLT format created differentiation but did not preserve long-term exclusivity.
- Merck does not separately disclose a reliable current MAXALT revenue line.
- New CGRP therapies compete for patients, but low-cost generic triptans remain commercially relevant.
- Current value lies in generic rizatriptan demand, not in an enforceable branded patent moat.
FAQs
Is MAXALT still available in the United States?
Generic rizatriptan remains available in the United States. The original MAXALT brand has a limited or discontinued commercial presence, depending on dosage form and channel.
Is rizatriptan the same drug as MAXALT?
Yes. Rizatriptan is the active ingredient in MAXALT. Generic rizatriptan is approved to be therapeutically equivalent to the applicable reference product.
Did MAXALT have pediatric exclusivity?
FDA pediatric exclusivity may have extended certain regulatory protections associated with the product. Any extension was temporary and did not prevent eventual generic entry after the relevant patent and exclusivity periods ended.
Can a company launch a new MAXALT formulation?
A company can develop a new rizatriptan formulation, but commercial protection would need to come from new patents, regulatory exclusivity, clinical differentiation or a delivery advantage. The existing MAXALT brand alone does not provide current market exclusivity.
Is MAXALT more valuable than generic sumatriptan?
No on a current asset basis. Generic sumatriptan and generic rizatriptan are both mature triptan products. Relative value depends on prescription volume, reimbursement, dosage-form mix, manufacturing cost and supplier concentration rather than brand patent protection.
References
- U.S. Food and Drug Administration. (2024a). MAXALT-MLT (rizatriptan benzoate) prescribing information.
- U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2024c). Drugs@FDA: MAXALT and MAXALT-MLT application records.
- Merck & Co., Inc. (Various years). Annual reports and Form 10-K filings.
- United States Patent and Trademark Office. (1994). U.S. Patent No. 5,298,532, pharmaceutical compounds and compositions.
